ACHIEVE Trials Demonstrate Comparative Benefits of Novel, Small Molecule Oral GLP-1 RA, Expanding Oral Treatment Options for Patient Population in Need of Alternative Solutions
by Prateek Chopra | July 1, 2026 | Diabetes Conferences | ADA 2026 Therapy Overview ACHIEVE Clinical Programme ACHIEVE-2 Findings (n=962) ACHIEVE-3 Findings (n=1,968) ACHIEVE-5 Findings (n=546) Safety Profile Clinical Implications The ACHIEVE programme demonstrated that oral orforglipron delivers substantial HbA1c reductions, meaningful weight loss, and favorable cardiometabolic benefits. These findings support its potential as an effective oral alternative to […]